

# PCDS

## Primary Care Diabetes Society

The latest news and views from the Primary Care Diabetes Society

### **Report from the 69<sup>th</sup> Scientific Sessions June 5–9 2009, New Orleans, Louisiana**



*Colin Kenny is a GP, Dromore, County Down, Northern Ireland, and a member of the PCDS Committee*

This meeting was held over a long weekend in new Orleans, a hot humid city, only partially recovered from hurricane Katrina.

The main trials that were presented are summarised below as well as clinical updates discussed at the meeting.

#### **RECORD study**

The main message from this study is that although rosiglitazone does increase the risk of heart failure and some fractures, it does not increase the risk of overall cardiovascular morbidity or mortality compared with standard glucose-lowering drugs (Home et al, 2009).

#### **BARI 2D trial**

No definitive benefit was seen implementing an insulin-sensitising versus an insulin-providing strategy. Despite an overweighting of participants treated with rosiglitazone in this trial, no increased cardiovascular risk was seen, and interestingly, no excess fracture risk was seen in this patient population (Pop-Busui et al, 2009).

#### **The Look AHEAD trial**

For the clinician in practice, the take-home messages in this study are that meal replacements are a valuable adjunctive technique for ongoing weight loss, and physical activity remains essential in successfully managing overweight people with diabetes (Wadden et al, 2009).

#### **Clinical updates discussed:**

- It was suggested that bariatric surgery should be renamed metabolic surgery as it can resolve diabetes (220 000 Americans underwent this surgery last year).
- Liraglutide may be slightly more effective than exenatide when compared head-to-head (Buse et al, 2009).
- In the FIELD study there were significantly fewer amputations in the fenofibrate group (Rajamani et al, 2009).
- Use of aspirin routinely in diabetes is still open to debate. The results of the ASCEND study will add more evidence to the debate.
- Posters confirmed that at least three more dipeptidyl peptidase-4 inhibitors, two more glucagon-like peptide-1 receptor agonists and inhaled insulin are all in phase 2 or phase 3 trials.
- The American Diabetes Association would like to use HbA<sub>1c</sub> levels alone to diagnose diabetes. This is still being debated.

Home PD, Pocock SJ, Beck-Nielsen H (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. *Lancet* 373: 2125–35

Pop-Busui R, Lu J, Lopes N et al (2009) Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. *J Peripher Nerv Syst* 14: 1–13

Wadden TA, West DS, Neiberg RH (2009) One-year weight losses in the Look AHEAD study: factors associated with success. *Obesity (Silver Spring)* 17: 713–22

Buse J, Sesti G, Schmidt WE et al (2009) Switching from twice-daily exenatide to once-daily liraglutide improves glycemic control in T2D on oral agents. *Diabetes* 59:1–P

Rajamani K, Colman PG, Li LP et al (2009) Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. *Lancet* 373: 1780–8

### **Submit your applications for PCDS committee elections**

To stand for election to the PCDS committee please submit a resumé of up to 150 words which will be used as an “election address” along with a recent photograph. The deadline for submitting your resumé is Friday 18 September (18.09.2009). The election will close on the Friday evening of the National Conference of the Primary Care Diabetes Society, 20 November 2009.

Please post your entries to:

The Primary Care Diabetes Society, SB Communications Group, 3.05 Enterprise House, 1–2 Hatfields, London SE1 9PG or fax to: 0207 627 1570 or email to: holly@sbcommunicationsgroup.com

### **Call for poster abstracts 5<sup>th</sup> National Conference of the Primary Care Diabetes Society**

Entries should be submitted electronically by 25 September 2009. For details and entry requirements, please see the PCDS website: [www.pcdsociety.org](http://www.pcdsociety.org).

The posters will be judged at the conference and the best entry will be presented with an award and the right to free registration for two people to all PCDS events in 2010.

Email entries to Holly Boyd: [holly@sbcommunicationsgroup.com](mailto:holly@sbcommunicationsgroup.com)